In early June, doctors in Ituri Province, DRC, confronted patients with classic Ebola symptoms—vomiting, diarrhea, bleeding—but standard GeneXpert assays repeatedly returned negative. Samples eventually reached Kinshasa’s National Institute of Biomedical Research, where a broader panel identified the Bundibugyo species, a strain the initial test could not detect. By then the virus had crossed into Uganda, prompting a public‑health emergency.

Health‑minister Samuel‑Roger Kamba announced the Bunia lab now processes 150 samples daily on four machines, eliminating backlogs, yet most specimens arrive from clinics rather than community tracing. In May, Kinshasa scientists employed South Korean RADI-One technology, which detects all four human Ebola species and Marburg, and the WHO is arranging a dozen more units. Cepheid pledged 5,000 kits, awaiting Congolese approval.

The episode underscores chronic under‑investment in pan‑species Ebola diagnostics, a gap that deters private firms because the market resides in low‑income settings. Unitaid’s pandemic‑preparedness chief warned that without rapid, field‑deployed tests, isolation wards mix Ebola with malaria or typhoid, fueling transmission and eroding community trust. Until affordable, multiplex kits reach frontline labs, containment will remain fragile, risking further cases and even death for patients.